BioCardia, Inc. Deferred Revenue (Non-Current)
BioCardia, Inc. (BCDA) had Deferred Revenue (Non-Current) of $683.00 thousand as of 2020-09-30, per its 10-Q filed 2020-11-10.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent › Deferred Revenue, Noncurrent
us-gaap:DeferredRevenueNoncurrent · last filed 2020-11-10
- 2020-09-30: Deferred Revenue, Noncurrent $683.00K.
- 2020-06-30: Deferred Revenue, Noncurrent $689.00K.
- 2020-03-31: Deferred Revenue, Noncurrent $689.00K.
- 2019-12-31: Deferred Revenue, Noncurrent $691.00K.
| Period end | Deferred Revenue, Noncurrent |
|---|---|
| 2020-09-30 | $683.00K 10-Q · filed 2020-11-10 |
| 2020-06-30 | $689.00K 10-Q · filed 2020-08-13 |
| 2020-03-31 | $689.00K 10-Q · filed 2020-05-15 |
| 2019-12-31 | $691.00K 10-Q · filed 2020-11-10 |
| 2019-09-30 | $691.00K 10-Q · filed 2019-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |